Alaunos Therapeutics (TCRT) Stock Price, News & Analysis

Company Overview

Alaunos Therapeutics, Inc. was a clinical-stage biotechnology company focused on developing genetically engineered T-cell therapies for cancer. Its primary research centered on T-cell receptor (TCR) therapies designed to recognize cancer-associated antigens and target solid tumors, an area that has historically been challenging for cell therapy developers.

The company’s technology portfolio included the Sleeping Beauty nonviral gene-transfer system, which was intended to introduce tumor-targeting TCRs into a patient’s T cells. Alaunos also pursued personalized therapies targeting tumor-specific mutations, commonly known as neoantigens, and evaluated its programs through collaborations and clinical research involving academic and medical institutions, including the National Cancer Institute.

Alaunos was formerly known as Ziopharm Oncology and adopted its current name in 2022. The company was headquartered in Houston, Texas, and its programs were primarily directed toward patients with advanced cancers in the United States. Alaunos subsequently reduced operations and reassessed its development strategy, and publicly available information about its ongoing programs and leadership is limited.

Key Stats

• Today's Range: $1.02 to $1.60
• 50-Day Range: $1.20 to $2.13
• 52-Week Range: $1.02 to $4.59
• Volume: 32.57 million shs
• Average Volume: 769,654 shs
• Market Capitalization: $3.05 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: Sell

Alaunos Therapeutics Stock Analysis - MarketRank™

Alaunos Therapeutics scored higher than 22% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 0.7 / 5
• Analyst Rating: Sell

Consensus Rating

Alaunos Therapeutics has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.

Amount of Analyst Coverage

Alaunos Therapeutics has only been the subject of 1 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Book Value per Share Ratio

Alaunos Therapeutics has a P/B Ratio of 1.29. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 5.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

0.27% of the float of Alaunos Therapeutics has been sold short.

Short Interest Ratio / Days to Cover

Alaunos Therapeutics has a short interest ratio ("days to cover") of 0.35, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Alaunos Therapeutics has recently decreased by 54.39%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Alaunos Therapeutics does not currently pay a dividend.

Dividend Growth

Alaunos Therapeutics does not have a long track record of dividend growth.

News and Social Media

• Score: 3.6 / 5
• News Sentiment: 0.78

News Sentiment

Alaunos Therapeutics has a news sentiment score of 0.78. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 5 news articles for Alaunos Therapeutics this week, compared to 1 article on an average week.

Search Interest

Only 1 people have searched for TCRT on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

MarketBeat Follows

1 people have added Alaunos Therapeutics to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.9 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Alaunos Therapeutics insiders have not sold or bought any company stock.

Percentage Held by Insiders

16.14% of the stock of Alaunos Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

27.72% of the stock of Alaunos Therapeutics is held by institutions.

Company Calendar

• Last Earnings: 8/14/2026
• Today: 9/19/2026
• Next Earnings (Estimated): 11/17/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:TCRT
• CIK: 1107421
• Web: www.alaunos.com
• Phone: (346) 355-4099
• Fax: 617-241-2855
• Employees: 1
• Year Founded: 2005

Profitability

• EPS (Trailing Twelve Months): ($1.91)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$4.18 million
• Net Margins: N/A
• Pretax Margin: -133,666.67%
• Return on Equity: -232.60%
• Return on Assets: -158.99%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 0.77
• Quick Ratio: 0.77

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $0.93 per share
• Price / Book: 1.29

Miscellaneous

• Outstanding Shares: 2,540,000
• Free Float: 2,130,000
• Market Cap: $3.05 million
• Optionable: No Data
• Beta: -0.97